/
/
Rift Vadisi Ateşi Virüsü Aşı Güvenliği ve Etkinliği Artırmak İçin MP-12 Gerinim NSS Gen işleyin Ters Genetik kullanma
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Chapters
- 00:05Title
- 01:57Preparation of Recombinant MP-12 Encoding NSs Mutations
- 03:38Amplification of P0 Virus
- 04:16Titration of Recombinant MP-12 by Plaque Assay
- 06:01Screening of NSs Mutants Lacking the Type-I IFN Suppression Function
- 07:03Reverse Genetics Approach to the C13type MP-12 Virus
- 08:22Conclusion
Tags
Reverse GeneticsNSs GeneRift Valley Fever VirusMP-12 StrainVaccine SafetyVaccine EfficacyHemorrhagic FeverNeurological DisordersBlindnessAbortionFetal MalformationHHS/USDA Overlap Select AgentRisk Group 3 PathogenPhlebovirusBunyaviridae FamilyVirulentRVFV MP-12 Vaccine StrainWild-type RVFV StrainsZH548ZH501M-segmentL-segmentS-segment RNA3Functional Virulence Factor NSsRMP12-C13typeIn-frame Deletion Of NSs ORFHost Transcription Shut-offInterferon (IFN)-beta MRNA78Double-stranded RNA-dependent Protein Kinase (PKR)Post-translational Level Degradation Of PKR
